Non-alcoholic fatty liver disease

NOSTER Research: Gut bacteria derived metabolites offer alternative treatment for fatty liver disease

Retrieved on: 
Monday, November 27, 2023
Research, Scar, Gene, Cirrhosis, Mouse, Liver, Liver disease, HYA, Non-alcoholic fatty liver disease, Patient, Pioglitazone, Obesity, Linoleic acid, TGF, Hepatic stellate cell, Bacteria, Death, Shizuoka University, Lactobacillus, Scientific Reports, Inflammation, Fibrosis, Dietary supplement, Vaccine, NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.

Key Points: 
  • Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
  • A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
  • Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
  • A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.

NOSTER Research: Gut bacteria derived metabolites offer alternative treatment for fatty liver disease

Retrieved on: 
Monday, November 27, 2023
Research, Scar, Gene, Cirrhosis, Mouse, Liver, Liver disease, HYA, Non-alcoholic fatty liver disease, Patient, Pioglitazone, Obesity, Linoleic acid, TGF, Hepatic stellate cell, Bacteria, Death, Shizuoka University, Lactobacillus, Scientific Reports, Inflammation, Fibrosis, Dietary supplement, Vaccine, NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.

Key Points: 
  • Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
  • A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
  • Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
  • A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.

Non-alcoholic steatohepatitis (NASH) real-world evidence innovation further extends Verantos' lead in artificial intelligence for cardiometabolic conditions

Retrieved on: 
Monday, November 13, 2023
RWE, Hepatology, PALO, NAFLD, Natural language processing, Organization, Prevalence, AASLD, DSM-IV codes, Patient, RWD, American Liver Foundation, Intelligence, Obesity, Non-alcoholic fatty liver disease, Chronic liver disease, NASH, Medical device

PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos, the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions. The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.

Key Points: 
  • PALO ALTO, Calif., Nov. 13, 2023 /PRNewswire/ -- Verantos , the global leader in high-validity real-world evidence at scale, today announced the presentation of an abstract on the use of artificial intelligence in cardiometabolic conditions.
  • The technology enables researchers to gather high-quality real-world data on NASH, non-alcoholic fatty liver disease (NAFLD), and related conditions.
  • "Verantos' advances in artificial intelligence afford life sciences organizations unprecedented real-world insights into metabolic diseases," said Dan Riskin, M.D., CEO of Verantos.
  • The number of cases is growing with the increasing prevalence of obesity and type 2 diabetes.

AI Revolutionizes Non-Alcoholic Steatohepatitis (NASH) Diagnosis and Treatment, Fueling Impressive 53.49% CAGR - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Health, Pharmaceutical, Stroke, Mayo Collaborative Services v. Prometheus Laboratories, Inc., AstraZeneca, Incidence, Compound annual growth rate, Liver, Therapy, Vitamin E, Cirrhosis, Medicine, Prevalence, Conditional sentence, ONE, Vitamin, Inflammation, Exercise, Hepatitis, Drug development, Non-alcoholic fatty liver disease, NASH, Clinical trial, Liver cancer, COVID-19, Risk, Novartis, Pharmacy, NAFLD, Cell damage, Diagnosis, Intercept Pharmaceuticals, Pharmaceutical industry, Dietary supplement, Medical device, Others, Pioglitazone

The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.

Key Points: 
  • The global Non-Alcoholic Steatohepatitis (NASH) market is poised to achieve a market value of US$2.71 billion by 2023, demonstrating an impressive Compound Annual Growth Rate (CAGR) of 53.49% over the projected period.
  • NASH, often referred to as "Silent Liver Disease," is a liver disorder caused by long-term alcohol abuse but mainly impacts non-alcoholics.
  • It is the second stage of Non-Alcoholic Fatty Liver Disease (NAFLD), marked by liver inflammation and cell damage.
  • As a result, there was an increased demand for NASH treatment, diagnostic tools, and emerging drugs, positively impacting the market.

AMRA Medical at AASLD The Liver Meeting® Showcases MRI-Based Technology and Muscle Biomarkers linked to liver disease severity and progression

Retrieved on: 
Thursday, November 9, 2023
Research, Surgery, Medical Devices, Clinical Trials, Health Technology, Biotechnology, Radiology, Health, Science, MELD, DSM-IV codes, Biomarker, Cirrhosis, Liver, Prevalence, Non-alcoholic fatty liver disease, Frailty, Liver disease, Phenotype, Multimedia, CVD, Circulatory system, Bilirubin, Mass, Type 2 diabetes, Cardiovascular disease, Abstract, AASLD, NAFLD, Patient, Sarcopenia, Medical imaging, Dietary supplement, T2D

A total of nine abstracts will be presented, focusing on how AMRA’s MRI-based muscle assessment score (MAsS) biomarkers are linked to liver disease severity and progression.

Key Points: 
  • A total of nine abstracts will be presented, focusing on how AMRA’s MRI-based muscle assessment score (MAsS) biomarkers are linked to liver disease severity and progression.
  • View the full release here: https://www.businesswire.com/news/home/20231109684555/en/
    The abstracts present MAsS as a promising tool to identify physical frailty and sarcopenia and as prognostic biomarkers for liver disease.
  • The AASLD’s The Liver Meeting® takes place November 10-14th in Boston, USA, with a number of AMRA attendees.
  • Those joining us at The Liver Meeting® can learn about how the MAsS biomarkers, muscle fat infiltration and muscle volume z-score, have been utilized in studies from early to end-stage liver disease.

Rising Diabetes Cases Drive Robust Growth in the Global Glucagon-like Peptide 1 (GLP-1) Market: A CAGR of 6.48% Expected - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Diabetes, Pharmaceutical, Health, Eli Lilly and Company, Ageing, Plasma, Half-life, AstraZeneca, Food, Obesity, Hypothalamus, Non-alcoholic fatty liver disease, Weight loss, Prevalence, Research, Exercise, Type 2 diabetes, Enzyme, Inflammation, Pfizer, Fatty liver disease, Conditional sentence, NASH, Thirst, COVID-19, Risk, DPP, Glucagon-like peptide-1, Diet, Liraglutide, NAFLD, Dulaglutide, Sanofi, Safety, Patient, Compound annual growth rate, Novo Nordisk, Appetite, Insulin, Dietary supplement, Pharmaceutical industry, Semaglutide

GLP-1 receptor agonists represent a class of non-insulin medications employed in conjunction with diet and exercise to manage type 2 diabetes.

Key Points: 
  • GLP-1 receptor agonists represent a class of non-insulin medications employed in conjunction with diet and exercise to manage type 2 diabetes.
  • Trulicity holds the largest market share due to the increasing prevalence of type 2 diabetes, driving demand for effective treatments.
  • The global GLP-1 market encompasses five major regions: North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa.
  • The prevalence of diabetes has surged, particularly in low- and middle-income countries, boosting demand for diabetes medication, thereby propelling the global GLP-1 market.

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, November 7, 2023
FDA, Research, Hepatitis B virus, Principal investigator, University of Oxford, Heart rate, Three Months, Obesity, RNA, Diabetes, Fast Track, Weight loss, EST, Blood pressure, Fibrosis, CHB, Liver disease, Exercise, Endocrine & Metabolism Research Institute, NASH, Risk, Diet, Arrhythmia, HBV, NAFLD, Safety, Overweight, Vital signs, Medicine, Investment, Waist, Human, Non-alcoholic fatty liver disease, DNA, Clothing, Cryptocurrency, Dietary supplement, Pharmaceutical industry, Vaccine, Rare-earth element, Webcast, HBsAg

GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update.

Key Points: 
  • Webcast to be held today, November 7, 2023, at 8:30 am EST
    GAITHERSBURG, Md., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended September 30, 2023, and provided a business update.
  • Top-line results after 24 weeks of treatment are expected in the first quarter of 2025.
  • Financial Results for the Three Months Ended September 30, 2023
    Cash, cash equivalents and short-term investments totaled $140.8 million as of September 30, 2023.
  • General and administrative expenses were consistent period-over-period at $4.5 million for the three months ended September 30, 2023 and 2022.

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 6, 2023
Coordinated Specialty Care, FDA, Non-alcoholic fatty liver disease, Research, Nine Months, Biomarker, Therapy, Cirrhosis, Agency, Treatment, Histology, Priority review, Disease, Hepatology, NASH, Fibrosis, Employee compensation in the United States, Incremental cost-effectiveness ratio, New Drug Application, Intelligence, Diabetes, NAFLD, Atherosclerosis, Fatty liver disease, Electronic health record, Pharmaceutical industry, Cryptocurrency, Medical imaging, Rare-earth element, Risk, Patient, Sanofi, Nature Medicine, Dupilumab, Madrigal

At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.

Key Points: 
  • At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.
  • The Agency noted that it is not currently planning to hold an advisory committee meeting to discuss the application.
  • In October 2023, we completed a public offering and received an additional $472.0 million in net cash proceeds.
  • These increases in interest income were due primarily to higher average interest rates in 2023.

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

Retrieved on: 
Friday, November 3, 2023
Hepatocyte, Hynes Convention Center, American Association for the Study of Liver Diseases, Therapy, Hepatology, Liver, Pharmacokinetics, Sarcopenia, Safety, GALT, Glomerular filtration rate, GA 2, AM, Abstract (summary), Obesity, Indiana University School of Medicine, Cirrhosis, Data monitoring committee, Disease, Hepatic hydrothorax, Medical school, Indiana University, SC 4, K–Ca dating, Non-alcoholic fatty liver disease, AASLD, Dietary supplement, Pharmaceutical industry, Flour, Patient

NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).

Key Points: 
  • NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD).
  • The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass.
  • “This year again we are happy to share some of the progress we have made in our global program with belapectin, our galectin-3 inhibitor.
  • We are also proud to bring additional knowledge to the field regarding liver cirrhosis, a disease that dramatically affects the lives of our patients and has been neglected for far too long,” said Pol Boudes, M.D., Chief Medical Officer of Galectin Therapeutics.

Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D

Retrieved on: 
Monday, November 6, 2023
TC, PD, UDCA, Hepatology, Ursodeoxycholic acid, AST, Primary biliary cholangitis, PBC, Pharmacokinetics, Phase, American Association for Geriatric Psychiatry, NASH, GGT, Medicine, Non-alcoholic fatty liver disease, FXR, NAFLD, Obeticholic acid, Safety, ALT, Patient, OCA, Diagnosis, FGF19, New England, Pharmaceutical industry, Gannex

In-house developed by Gannex, ASC42 is a novel non-steroidal, selective, potent FXR agonist with best-in-class potential and global intellectual property.

Key Points: 
  • In-house developed by Gannex, ASC42 is a novel non-steroidal, selective, potent FXR agonist with best-in-class potential and global intellectual property.
  • On July 20, 2023, Gannex announced the completion of patient enrollment for Phase II clinical trial of ASC42 for PBC.
  • The Phase II clinical trial of Gannex's in-house developed farnesoid X receptor agonist ASC42 will be completed soon.
  • The topline data of the Phase II clinical trial are expected to be released by the end of 2023.